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P(atelet.Actlve Agents end Their Evetuetton 
8:30 
['8~1_.-" - -~  Unexpected, Discordant Effects of Aspirin on 
Platelet Reactivity 
T,P F~rmll, K,A, Hayes, P,B, Trncy, B,E, 9obol, D,J, Schneider, University of 
Vermont, Blurllngton, VT, U~A 
B~ckgrovnd: Chnmotoritation of plnlal~I f~,n¢llon tn re~prmso to nnliplnlelet 
agonl~ h~S t~en ehmNe, To determine whether e~fnctn of nsplrln are con~is. 
toni, we quantified both platolol ~otlvallon I  whole blood with flow cytomolry 
to detect P.solectin oxpteoolon ~nd plntolot ,lggmg~tlon (by nggmgomotry in
pl~tolot.rloh plasmt~) tn healthy subjects before ~nd niter 5 dP, ys el lroatmont 
with ~splrln (A~A, 81 and 325 mg qd) er Ti¢~ltd (~50 mg bid), 
Mothed,~ ~nd Results: B(t~t~l nnmplon wore drawn alter a t0 day drug 
fmo Interval, Both platolot activation and aggregrttion worn induced with law 
rather lh~n conventional s~praptty~tologto concentrations el ADP (. 2 .  M), 
Anti~oogulation was wlth corn IWpstn inhR~itor qsed to inhibit only Factor 
XIl~ ~nd hence the confetti pr~lhwffy, Responses to A9A worn discord~nt 
45% of ~ubla(~ta warn non.m~pondom, 33% ware respondors, and ~2% 
w~re p~radoxioal respondoro, Ro~pondem showed both dot~re~sod platelel 
activation and aggregation with A~A (% central with ~,5 mg A~A', activation 
5~ :t 7%, ~ggregatirm = ;'3 t 3%, p • 0,001 lot both), Paradoxical 
m~pond~m ~howt~d decreased activation with 81 mg A~A (4~ 11%, p " 
0,01) b~tt incmaood activ,ltian with 325 mg A~A (248 ~l 4tt, p., 0,05), both 
paralleled by co11'osponding chnngo~ tn aggregation, h~ all subincts, T~clid 
decreased both activation and nggmgrttlrm, 
Conct~lon: Thos, responses to nntiplalelet therapy dlllor markedly among 
Indlvldtl~l~ with dlroctionally opposite Itects occurring m SOmO with different 
dose~ el the same agent 
8:45 
~7t=.~2-2 Differential Doaa Effect o! Aspirin in the Primary 
Prevention o! Myocardial Infarction 
FWA. Verhougt, Dnpar/ment ot Cnrdtolog~ Umvomity Hospital. Nvme,qen, 
Th~ Netherlan~ 
By intodenng with platotot aggregation aspmn is offochvo in the secondary 
ned primary prevention of acute myocardial infnmtion. Since coronan/plaque 
rupture may be mediated by immunocompotont coils like monocytos, the an- 
t,nflnmmntory effect of high dose ~spinn may also contnbute to the protection 
against myocardial infn~tion, but this has never boon evaluated in humans. 
To test this hypothesis in the pnmary prevention of myocardial inlarcbon 
cdt 28 suitable rnndem(zod controlled tnals with noncoronary patients and 
hoaffhy individuals from the Antiplatolet Tnalists' Collaboration were analyzed 
on ~spinn dose in relation to the efficacy in the prevention of myocardial 
toleration. Both indirect compansons with plncobo ned direct companson 
between aspmn dose rag=mona were made. 
High dose (600 to 1,500 mg daily) aspinn was compared to placebo in 
10,680 patients in 21 ranis and found to reduce the incidence of myocardial 
infamtion (RR 0.76, 95% CI 0.60-0.96). Low dose (500 mg or loss) aspmn 
was compared to placebo in 29.201 individuals in 5 teals and found to reduce 
ffto incidence of myocardial infarction (RR 074, 95% CI 0.63-088), In 1,753 
patients in 2 tnnls high dose regimens were directly compared to low dose 
aspmn and not tound to be more effective (RR 1.33, 95% CI 0.84-254, see 
figure). 
INDIRECT COMPARISON DIRECT COMPARISON 
Thus, in both direct dose comparisons and indirect placebo comparisons 
high dose a.cpmn does not p~event my~.cardial infarction more effectively 
than tow dose aspirm The antiphlogistic action of high dose aspirin does not 
seem to contribute to the prevenhon of myocardial infarction, the inflammatory 
origin of which is still under debate. 
g:o0 
~ Combination of Boraproat Sodium, an Orally 
Available Prostacyclln Analogue, With Aspirin, 
A Now Promising AntI-Platelfll Prescription Against 
Stroke and Atherosclsrosls? 
Y, Aknlshl, I. Sakomn, M. Fukno, A, KitebRt.ke, Hokk~ido Univemity ~hoot  
of Medicine, Sappom, Japnn 
Background; Aspinn InhiblI~ thrombox{mo A~ (TXA~) .dopoodent O) pl~tot(~t 
oggrog~tion tAG), however, it c~n inhibit prostncyclin (PGIo) synthase and 
thus may promote pl~telet AG and ntherosolamsis, We aimed to tnvost=g,~te 
wholhar n PGt.~ ~natoggo, bomprost sodium (BPS), givQl~ to humans in 
¢ombin[ttirm with aspirin exollt~ beneficial offecls on platolot functions without 
causing senous ndvomo reactions, 
Mpfhed~: Aspirin (81 rag, pQr as) and BPS (40 I,g, per as) were galen 
None at in comblnRtlon to male vo!ontee.m (n = 8), We checked 1) platelet 
AG induced by ADP, cellogon (COl..) and thrombin (THR), 2) pl.'tlelet cy. 
tosottc Ca ~* ([Ct~ * ]i) mobdizatton induced by THR and COL and 3) plasma 
concnnlmtions of TXB~ and 6-kete-PGFt ,w, 
Ro.~uI~: ~ingt~ adminislration of QPS inhib!ted bo!h TX/~,O and TXA.~,ln. 
dependent lID) AG by 20% and ~1%, respectively. Aspmn pretemntmffy 
mhibitod TXA~.D AO (60%) compared with TXA:~.!D AG (- 12%). Comb,- 
nation el aspirin and BPS o~ode(t an additive effect on mhib~tlon o| piatelet 
AG (TXA~-D AG: 84%, TXA~.ID AG: ~%). Increaser in [Ca ~,li inducml 
by THR, and COL worn Inhibited by aspirm and/or BPS in a manner parallel 
to theft lnhibitoq/effects on platole! AG. Aspirm and/or BPS did not ruo~ 
plasma 6 kefo,PC~F t ~, !ovals, and asptnn signihcantly reduced plasm~ TXB2 
levels by St%. Combination el aspinn and BPS d~d not cause any malor 
advemo reactions uch as bleeding 
Conclusion: Oral administration ot BPS in combination with aspinn ex. 
erred ~tent antt-plntelet ffects odditivo to those elicited by aspmn alone. 
This combination would be clinically useful to prevent hrombosis and pro- 
gression ot atherosctemsis because 1 ) =t enhances anti-aggmgatm O effe¢ls el 
aspinn which ~S relatively weak, 2) ~t may compensate for the asp inn- i~  
reduction el ondogeoous PGI;, and 3) it is sate without causmg e~cess~,,e 
synergistic reactions. 
9:15 
~ Safety of 10 Days of Ticlopldine Alter Coronary 
Stentlng - A Randomized Comparison With 30 Days: 
Strategic ALternatives With Tlclopidine in _Stenting 
Study (SALTS) 
GY.F Szto, T.J. Linnemeier. S.J. Lewis, KK  Punamiya. SC. Jun 9, 
DA. Rothbaum. RJ. Landin. M.W. Ball. R.V Rtddell. Z.I. Hodes. DL. Lips. 
G.B. Eisner, M. Potnku~, J.L Coverdale St Vrncent Hospital Indiana Heart 
InsHute. Ind~anapohs. IN. USA 
Purpose: Thrdy days of Ttclopldlne (TIC) can result in fatal neutropema 
(NEUT). Subacute slant thrombosis (SST) tends to occur within 10 clays ot 
stentmg. We postulated that 10 days ot TIC may be sufficient o prevent SST. 
yet reduce the likelihood of developing NEUT. 
Methods: Pts were randomized to aspirin (325 mg q.d.) and tO or 30 days 
of TIC (250 mg b.l.d) post elective Palmaz-Schatz stent (-~2) placement 
Post-steer high-pressure balloon inflations were used (no IVUS used in any 
pts). Exclusion cntena include LVEF ~ 30=0, AMI within 2 days el stenting and 
cabal lesions. Complete blood counts were requested at 2, 4 and 6 weeks 
attar discharge in all pts. 
Results: To date, 30-day follow-up results of 99 pts: 
10 days TIC IN : 50) 30 days TIC (N = 41) P Value 
Ago (yrs);Males (°o) 61 ~6"t 63JSS NS'NS 
Stable!Unstable Angln,'~ 36"~s47% 24°~ 56"~ NS, NS 
Recent MI (%) 17 15 NS 
LVEF t%) 48 49 NS 
Slant in CABG (% of pts) t 7 ? NS 
Stoat diameter (am) 3 3 3 4 NS 
Numbe, o! slants;case 1 3 t 3 NS 
Meier adverse vents" 1 3 0 03 
• 10 day TIC - thrombocytopenia: 30 day TIC - SST. NEUT. death 
Conc/v~on: Ten dayc, ot TIC post Palmaz Schatz stenting ts sate and 
effective. Further data will determine it NEUT or TCP is reduced using only 
10 days of TIC. Completed study results will be available by 3/98. 
